Evaluation of the Efficacy and Safety of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease
Public ClinicalTrials.gov record NCT04036292. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Multicenter, Randomized, Controlled, Double-Masked, Clinical Trial to Evaluate the Efficacy and Safety of OC-01 (Varenicline) Nasal Spray on Signs and Symptoms of Dry Eye Disease (The ONSET-2 Study)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The objective of this study is to evaluate the safety and effectiveness of OC-01 Nasal Spray as compared to placebo on signs and symptoms of dry eye disease.
Study identification
- NCT ID
- NCT04036292
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 758 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 22 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 22, 2019
- Primary completion
- Apr 9, 2020
- Completion
- Feb 4, 2021
- Last update posted
- Nov 21, 2021
2019 – 2021
United States locations
- U.S. sites
- 22
- U.S. states
- 18
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Phoenix | Phoenix | Arizona | 85032 | — |
| New Port Beach | Newport Beach | California | 92663 | — |
| Fort Collins | Fort Collins | Colorado | 80528 | — |
| Waterbury | Waterbury | Connecticut | 06708 | — |
| Delray Beach | Delray Beach | Florida | 33484 | — |
| Indianapolis | Indianapolis | Indiana | 46290 | — |
| Louisville | Louisville | Kentucky | 40206 | — |
| Raynham | Raynham | Massachusetts | 02767 | — |
| Las Vegas | Las Vegas | Nevada | 89052 | — |
| Raleigh | Raleigh | North Carolina | 27603 | — |
| Shelby | Shelby | North Carolina | 28150 | — |
| Fargo | Fargo | North Dakota | 58103 | — |
| Cranberry Township | Cranberry Township | Pennsylvania | 16066 | — |
| Warwick | Warwick | Rhode Island | 02842 | — |
| Sioux Falls | Sioux Falls | South Dakota | 57108 | — |
| Nashville | Nashville | Tennessee | 37210 | — |
| Austin | Austin | Texas | 78731 | — |
| Houston | Houston | Texas | 77025 | — |
| San Antonio | San Antonio | Texas | 78209 | — |
| San Antonio | San Antonio | Texas | 78229 | — |
| Layton | Layton | Utah | 84041 | — |
| Lynchburg | Lynchburg | Virginia | 24502 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04036292, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 21, 2021 · Synced Sep 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04036292 live on ClinicalTrials.gov.